scholarly journals The changing landscape of head and neck cancer radiotherapy patients: is high‐risk, prolonged feeding tube use indicative of on‐treatment weight loss?

2019 ◽  
Vol 66 (4) ◽  
pp. 250-258 ◽  
Author(s):  
Nigel J. Anderson ◽  
James E. Jackson ◽  
Morikatsu Wada ◽  
Michal Schneider ◽  
Michael Poulsen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Head And Neck Cancer ◽  
High Risk ◽  
Head And Neck ◽  
Neck Cancer ◽  
Feeding Tube ◽  
Cancer Radiotherapy ◽  
Prolonged Feeding

scholarly journals Sarcopenia, a strong determinant for prolonged feeding tube dependency after chemoradiotherapy for head and neck cancer

Head & Neck ◽  
2019 ◽  
Vol 41 (11) ◽  
pp. 4000-4008 ◽  
Author(s):  
Rebecca T. Karsten ◽  
Abrahim Al‐Mamgani ◽  
Sandra I. Bril ◽  
Sheena Tjon‐A‐Joe ◽  
Lisette Molen ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Feeding Tube ◽  
Tube Dependency ◽  
Prolonged Feeding

Association between salivary cytokine levels and chemoradiotherapy-induced toxicities in head and neck cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5555-5555
Author(s):  
Paolo Bossi ◽  
Paola Filipazzi ◽  
Carlo Resteghini ◽  
Rosalba Miceli ◽  
Ester Orlandi ◽  
...  
Keyword(s):  
Weight Loss ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Feeding Tube ◽  
Progressive Increase ◽  
Individual Values ◽  
Primary Tumor Site ◽  
Cytokine Levels ◽  
The Difference

5555 Background: Mucositis is a common complication of chemoradiotherapy (CTRT) for head and neck cancer (HNC), linked to a balance between pro- and anti-inflammation serum cytokines. No study has yet addressed the role of salivary cytokines in influencing toxicity severity. Methods: Twenty consecutive stage III (15%) and IV (85%) HNC patients (pts) were treated with radiotherapy (64-70 Gy) plus cisplatin (n=15), carboplatin (n=4) or cetuximab (n=1). Primary tumor site was oral cavity (15%), oropharynx (55%), nasopharynx (15%), larynx or hypopharynx (15%). Unstimulated saliva samples were collected according to standardized protocols before CTRT, during (3rd, 5th and 7th weeks) and two weeks after; concomitantly, mucositis grade (WHO classification), weight loss and need for feeding tube were evaluated. The salivary levels of 11 different cytokines (IFNγ, IL1β, IL2, IL4, IL5, IL6, IL8, IL10, IL12p70, TNFα and TNFβ) were analysed both in pts and in healthy donors (HD, n=10) by optimized bead-based multiplex immunoassay. The cytokine change during treatment was calculated as the difference between the mean of individual values and the baseline value. The Wilcoxon rank sum test was used for between-groups comparisons. Results: At baseline, no difference in cytokine levels was observed in pts as compared with HD, except IL8. A significant and progressive increase of IL1β, IL6, IL8, TNFα and IL10 levels was observed during treatment, with high levels persisting two weeks after treatment for all cytokines but IL1β. Significant association was shown between IL6 increase and G3/4 mucositis (p=0.009) or feeding tube need (p=0.04). The same trend was observed for TNFα. Interestingly, IL8 increase appeared to be specifically linked to weight loss (>10%, p=0.003). In contrast, baseline cytokine salivary levels were not predictive of treatment-induced toxicities. Conclusions: The increase of IL6, IL8 and TNFα salivary levels occurring in HNC patients with CTRT seems to be directly associated with mucositis severity, feeding tube prevalence and weight loss. Cytokines may represent a potential new target for preventive and/or therapeutic intervention.

scholarly journals Clinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancer

2020 ◽  
Vol 14 ◽  
pp. 1-10 ◽  
Author(s):  
James E. Jackson ◽  
Nigel J. Anderson ◽  
Morikatsu Wada ◽  
Michal Schneider ◽  
Michael Poulsen ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
High Risk ◽  
Risk Stratification ◽  
Head And Neck ◽  
Neck Cancer ◽  
Feeding Tube

Randomized Trials on Altered Fractionation in Head and Neck Cancer Radiotherapy with Conventional Fractionation as Control Arm: Another Lap to Go

1998 ◽  
Vol 84 (2) ◽  
pp. 160-166 ◽  
Author(s):  
Patrizia Olmi ◽  
Carlo Fallai
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Randomized Trials ◽  
Local Control Rate ◽  
Cancer Radiotherapy ◽  
Conventional Radiotherapy ◽  
Conventional Fractionation ◽  
Altered Fractionation ◽  
Accelerated Fractionation

The Authors present a review of randomized trials on non conventional fractionation in head and neck cancer radiotherapy with conventional fractionation as control arm. Hyperfractionation was studied in 5 trials, accelerated hyperfractionation in 4 trials and accelerated fractionation in 3 trials. Furthermore, the reviews of eminent Authors dealing with the above mentioned trials are summarized. In spite of improved local control rate reported with hyperfractionation, non conventional radiotherapy schedules are not yet recommended as routine clinical practice, but all the radiation oncologists are invited to join trials on this subject.

Assessment of adjuvant therapy in resected head and neck cancer with high-risk features

Oral Oncology ◽  
2017 ◽  
Vol 74 ◽  
pp. 15-20 ◽  
Author(s):  
Gaurav S. Ajmani ◽  
Cheryl C. Nocon ◽  
Chi-Hsiung Wang ◽  
Mihir K. Bhayani
Keyword(s):  
Head And Neck Cancer ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Head And Neck ◽  
Neck Cancer
Sign in / Sign up

Export Citation Format

Share Document